Sample records for aclarubicin

  1. Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16

    DEFF Research Database (Denmark)

    Petersen, L N; Jensen, P B; Sørensen, B S;


    to topo-II targeting drugs both when administered prior to and after the topo-II targeting agents. Thus, our data suggest that sequential rather than simultaneous administration of aclarubicin and topo-II targeting agents may be superior with respect to net-cytotoxicity.(ABSTRACT TRUNCATED AT 250 WORDS)......In previous studies, we found that VP-16 (etoposide) induced cytotoxicity and protein-concealed strand break formation was prevented in a small cell lung cancer (SCLC) cell line, when the cells were incubated with aclarubicin prior to treatment with VP-16. In the present work, we studied the effect...

  2. Radiotherapy combined with aclarubicin and neocarzinostatin for cancer of the gallbladder

    Energy Technology Data Exchange (ETDEWEB)

    Okuyama, Shin-ichi; Mishina, Hitoshi; Funaki, Ken-ichi; Mori, Toshihiko (Tohoku Rosai Hospital, Sendai (Japan))


    Cancer of the gallbladder is radioresistant. When it was found inoperable, she was subjected to radiotherapy combined with aclarubicin and neocarzinostatin. Therapeutic effectiveness was confirmed at autopsy as she later succumbed to uterine cervical cancer. Thus, the present radiochemotherapeutic regimen would probably provide a means of overcoming those radioresistant inoperable malignancies. Intravenous administrations of appropriate antibiotics such as azthreonam and reniran may probably be helpful in the prevention and treatment of septic peritonitis possible during the course of reinforced radiotherapy of the abdomen. (author).

  3. Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside.

    Directory of Open Access Journals (Sweden)



    Full Text Available Relapses in nine patients with acute myelocytic leukemia were treated with a combination of aclarubicin (ACR and cytosine arabinoside (ara-C. ACR, 40 mg/m2/day, was administered daily by intravenous injection from day 1 to day 3 and ara-C, 60-80 mg/m2/day, divided into 2 doses, was given every 12 h by intravenous infusion from day 1 to day 7. Depending on the state of the bone marrow, ACR-ara-C regimen was modified in administration period and repeated after the resting periods of at least 7 days. Complete remission was obtained in 7 of 9 patients (77.8%. The time required for achieving the complete remission varied from 20 to 55 days with a median of 39 days. The duration of complete remission was from 8 to 52 weeks with a median of 22 weeks. Side effects on digestive system such as nausea, vomiting and anorexia, were seen in all patients, although they were managed by symptomatic treatment. The results indicate the effectiveness of this ACR-ara-C regimen in the clinical management of acute nonlymphocytic leukemia.

  4. Efficacy and safety of the HAA regimen as induction chemotherapy in 236 de novo acute myeloid leukemia

    Institute of Scientific and Technical Information of China (English)



    Objective To evaluate the efficacy and safety of the HAA regimen (homoharringtonine,cytarabine and aclarubicin) as induction chemotherapy in de novo acute myeloid leukemia (AML) .Methods The efficacy and safety of 236 de novo AML patients who received the HAA regimen as induction chemotherapy were retrospectively analyzed.The complete remission (CR) rate was assayed.Kaplan-Meier method was used to estimate overall survival (OS) and relapse free survival (RFS) ,and the differ-

  5. Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients

    Institute of Scientific and Technical Information of China (English)

    Guang-sheng He; Xiang Zhang; De-pei Wu; Ai-ning Sun; Zheng-ming Jin; Hui-ying Qiu; Miao Miao; Xiao-wen Tang; Zheng-zheng Fu; Yue Han


    Objective To evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor(CAG)regimen for refractory biphenotypic acute leukemia(BAL).Methods We treated 5 refractory BAL patients by CAG regimen(10 mg·m 2 cytosine arabinoside subcutaneously administrated every 12 hours,day 1-14;5-7 mg·m2 aclarubicin intravenously administrated daily,day 1-8;and concurrently used 200 μg.m-2·d-1 granulocyte colony-stimulating factor subcutaneously)from November 2002 to April 2007.The efficacy of the regimen was evaluated by response rate,and the side effects were also measured.Results The complete remission rate was 80% ,median duration of absolute neutrophil count<5.0×108/L and platelet count<2.0×1010/L was day 13 and day 1,respectively;and the infection rate was low(Ⅲ-Ⅳ infection rate,20.00% ).Conclusion CAG regimen as remission induction chemotherapy for BAL patients is effective with a high remission rate and low toxicity.

  6. Production of a new hybrid anthracycline 4-O-methylepelmycin by heterologous expression of dnrK in epelmycin-producing Streptomyces violaceus. (United States)

    Miyamoto, Y; Ohta, S; Johdo, O; Nagamatsu, Y; Yoshimoto, A


    A new hybrid anthracycline antibiotic was produced by heterologous expression of dnrK encoding carminomycin 4-O-metyltransferase in an epelmycin-producing Streptomyces violaceus. pMK100 was constructed by insertion of Steptomyces peucetius dnrK gene in Steptomyces-expression vector pIJ6021 and introduced to the epelmycin producer. The transformant produced a hybrid anthracycline antibiotic together with host epelmycins when cultured in antibiotic production medium in the presence of thiostrepton. The hybrid anthracycline was determined to be 7-O-L-rhodosaminyl-4-O-methyl-epsilon-rhodomycinone (4-O-methylepelmycin D). However, the attempts on production of hybrid 4-O-methylaclarubicin and 4-O-methyl-1-deoxyobelmycin by the transformants of aclarubicin and 1-deoxyobelmycin producers with pMK 100 were unsuccessful. PMID:11079805

  7. Coadministration of the FNIII14 Peptide Synergistically Augments the Anti-Cancer Activity of Chemotherapeutic Drugs by Activating Pro-Apoptotic Bim. (United States)

    Iyoda, Takuya; Nagamine, Yumi; Nakane, Yoshitomi; Tokita, Yuya; Akari, Shougo; Otsuka, Kazuki; Fujita, Motomichi; Itagaki, Keisuke; Takizawa, You-Ichi; Orita, Hiroaki; Owaki, Toshiyuki; Taira, Jyunichi; Hayashi, Ryo; Kodama, Hiroaki; Fukai, Fumio


    The acquisition of drug resistance mediated by the interaction of tumor cells with the extracellular matrix (ECM), commonly referred to as cell adhesion-mediated drug resistance (CAM-DR), has been observed not only in hematopoietic tumor cells but also in solid tumor cells. We have previously demonstrated that a 22-mer peptide derived from fibronectin, FNIII14, can inhibit cell adhesion through the inactivation of β1 integrin; when coadministered with cytarabine, FNIII14 completely eradicates acute myelogenous leukemia by suppressing CAM-DR. In this study, we show that our FNIII14 peptide also enhances chemotherapy efficacy in solid tumors. Coadministration of FNIII14 synergistically enhances the cytotoxicity of doxorubicin and aclarubicin in mammary tumor and melanoma cells, respectively. The solid tumor cell chemosensitization induced by FNIII14 is dependent upon the upregulation and activation of the pro-apoptotic protein, Bim. Furthermore, the metastasis of tumor cells derived from ventrally transplanted mammary tumor grafts is suppressed by the coadministration of FNIII14 and doxorubicin. These results suggest that the coadministration of our FNIII14 peptide with chemotherapy could achieve efficient solid tumor eradication by increasing chemosensitivity and decreasing metastasis. The major causes of tumor recurrence are the existence of chemotherapy-resistant primary tumor cells and the establishment of secondary metastatic lesions. As such, coadministering FNIII14 with anti-cancer drugs could provide a promising new approach to improve the prognosis of patients with solid tumors. PMID:27622612

  8. Prediction of P-glycoprotein expression and chemoresistant character of gliomas by SPECT

    Energy Technology Data Exchange (ETDEWEB)

    Iuchi, Toshihiko; Togawa, Takashi; Oga, Masaru; Osato, Katsunobu [Chiba Cancer Center (Japan); Namba, Hiroki; Fujimoto, Shuichi


    In this prospective study of 25 malignant gliomas, we correlated the {sup 99m}Tc-MIBI uptake/{sup 201}Tl uptake ratio (MIBI/Tl) with the expression of P-glycoprotein in tumor tissue and the tumor's response to anticancer agents. All patients underwent {sup 99m}Tc-MIBI and {sup 201}Tl SPECT before surgery. Semiquantitative assessment of tracer uptake was performed using the ratio of radioactivity in the tumor relative to normal scalp. Immunohistochemical studies were performed on paraffin sections using an anti-P-glycoprotein monoclonal antibody, JSB-1. Chemosensitivity of the gliomas to following 12 anticancer agents: vincristine, vinblastine, vindesine, etoposide, irinotecan, daunomycin, adriamycin, aclarubicin, epirubicin, pirarubicin, actinomycin and mitoxantrone, was determined by an in vitro assay using surgical specimens, and chemosensitivity was expressed as the number of effective drugs. Gliomas expressing P-glycoprotein were significantly less chemosensitive than gliomas without the glycoprotein (p=0.010), and MIBI/Tl of gliomas expressing P-glycoprotein was significantly smaller than tumors without expression (p=0.008). From the prognostic point of view, gliomas showing MIBI/Tl of 0.6 or less had fewer effective drugs (p=0.008). However, MIBI/Tl was not effective at predicting overall survival in patients with malignant glioma. From these results, we concluded that efflux of {sup 99m}Tc-MIBI through P-glycoprotein could be evaluated by MIBI/Tl, and this index reflected well the chemoresistant character of malignant gliomas. (author)

  9. Curative effect of decitabine combined with CAG regimen in older patients with acute myeloid leukemia%地西他滨联合CAG治疗老年急性髓系白血病的疗效观察

    Institute of Scientific and Technical Information of China (English)

    于锦香; 蔡冬梅; 王晓雪; 梁颖; 张蕊; 颜晓菁; 何娟; 李艳


    目的 观察地西他滨联合CAG方案治疗老年急性髓系白血病的疗效和安全性.方法 7例老年急性髓系白血病患者应用地西他滨+ CAG方案[地西他滨15 mg/(m2·d),qd,iv,d1-5;阿克拉霉素10 mg/d,qd,iv,d3-6;阿糖胞苷10 mg/m2,q12h,ih,d3-9;G-CSF 300μg,qd,ih d0-9].观察患者疗效及不良反应.结果 2例使用4个疗程,2例使用3个疗程,1例使用2个疗程,2例使用1个疗程,其中2例获完全缓解,4例获部分缓解,1例疾病进展,最后因肺部感染死亡.结论 地西他滨联合CAG方案治疗老年急性髓系白血病,效果良好,安全性高,不良反应少,化疗相关死亡率低.%Objective To investigate the curative effect and safety of decitabine combined with CAG regimen treatment for elderly AML patients. Methods 7 cases of elderly AML patients were treated with decitabine combined with CAG regimen [decitabine 15 mg/(m2?d) ,qd,iv,d1-5 ,aclarubicin 10 mg/d, qd, iv, d3-6 , Ara-c 10 mg/m2 ,ql2h, ih, d3-9 , G-CSF 300 μg, qd, ih, d0.9]. Results 2 cases lasted for 4 courses, and 2 cases for 3 courses, 1 case for 2 courses and 2 cases for 1 course. There were 2 cases of CR,4 cases of PR,1 case of NR(died of lung infection). Conclusion Decitabine combined with CAG regimen is an effective treatment for the elderly AML patients with high safety and low treatment-related mortality.

  10. Clinical study of CAG regimen combined Decitabine in treatment of elderly patients with moderate and high risk myelodysplastic syndrome and acute myeloid leukemia%地西他滨联合小剂量化疗治疗老年中高危骨髓增生异常综合征及急性髓系白血病的临床观察

    Institute of Scientific and Technical Information of China (English)

    徐瑜; 沙颖豪; 谢彦晖


    Objective To observe the clinical efficacy and adverse events of treatment for elderly patients with moderate and high-risk myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AMD with Decitabine (25mg/d, d1-3) combined with CAG (G-CSF300ug/d, d4-13; aclarubicin10mg/d, d4,6,8,10,12; Ara-C25mg/d, d4-13) regimen. Methods Decitabine combined with CAG regimen were used to treat 10 elderly patients with MDS and AML. The outcome was evaluated after 1 course of treatment. Results For ten patients, 3/10(30%) achieved completely remission (CR), 4/10 (40%) marrow completely remission (mCR), 1/10 (10%) partial remission (PR). The overall response rate was 80%. Most patients can withstand adverse reactions occurred mainly for the arrest of bone marrow. Conclusion In older patients, medium and high-risk MDS and AML treated with Decitabine combined with CAG regimen is safe and effective.%目的 观察地西他滨联合CAG方案治疗老年中高危MDS及AML的临床疗效及不良反应.方法 应用地西他滨联合CAG方案治疗MDS及AML患者10例.1个疗程后评估疗效.结果 10例患者,其中3例获得完全缓解(CR) 30%,4例为部分缓解(PR) 10%,1例获得骨髓缓解(mCR)40%.总有效率为80%.大多数患者出现了可以耐受的不良反应,主要表现为骨髓抑制.结论 地西他滨联合CAG方案治疗中高危MDS和老年AML有较好的疗效和安全性.

  11. 地西他滨联合CAG方案治疗骨髓异常综合征临床研究%Clinical Study on the Treatment of Myelodysplastic Syndrome With the Combination of CAG and Decitabine

    Institute of Scientific and Technical Information of China (English)



    目的:研究地西他滨联合CAG(阿克拉霉素、阿糖胞苷及粒细胞刺激因子)方案治疗骨髓异常综合征临床效果。方法选择我院2013年4月1日~2015年10月31日收治的骨髓异常综合征患者42例作为研究对象,将患者分为两组,观察组21例和对照组21例,观察组患者应用地西他滨联合CAG方案进行治疗,对照组患者应用CAG方案进行治疗,比较两组的治疗效果。结果观察组不良反应发生率比对照组低,差异有统计学意义(P<0.05);观察组治疗有效率比对照组高,差异有统计学意义(P<0.05)。结论地西他滨联合CAG方案治疗骨髓异常综合征临床效果较好。%Objective To study the treatment of Myelodysplastic Syndrome with the combination of Decitabine and CAG(aclarubicin,cytarabine and Granulocyte Colony-Stimulating Factor).Methods Selected 42 patients with myelodysplastic syndrome treated from April 1st,2013 to October 31st,2015,as the research object,and divided the patients into two groups. Observation group 21 cases and the control group 21 cases,observation group of patients with application of Decitabine and CAG,patients in the control group used the CAG solution for treatment,then compared two groups of treatment effect.ResultsThe effective rate of the observation group was lower than the control group,the difference was significant(P<0.05). The incidence of adverse reactions of the observation group was higher than the control group,the difference was significant(P<0.05). Conclusion The efficacy of decitabine combined with CAG in the treatment of myelodysplastic syndrome is significantly.

  12. [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes]. (United States)

    Zhang, Yun-Ping; Wu, Wen-Zhong; Cui, Guo-Xing


    This study was purposed to compare the clinical efficacy and adverse reactions of low-dose decitabine combined with CAG regimen (aclarubicin, Ara-C, and G-CSF) and CAG regimen alone in intermediate to high-risk myelodysplastic syndromes (MDS), and evaluate the validity and efficacy of the former regimen as new treatment method of intermediate to high-risk myelodysplastic syndromes. A total of 12 patients with intermediate (IR) to high-risk (HR) MDS treated by low-dose decitabine combined with CAG regimen and 10 patients with IR to HR MDS treated by CAG regimen alone were evaluated after treatment of 1 cycle and at least after 2 cycles. The complete remission (CR) after 1 cycle, overall remission rate (ORR), progression free survival (PFS) and overall survival (OS) between them were analyzed. The results showed that 9 patients treated by low-dose decitabine combined with CAG regimen achieved complete remission after 1 cycle, 2 patients achieved partial remission, 1 patient did not show reaction. The complete remission rate was 75.0% and overall response rate was 91.7%. The median time of disease free survival was 9 months (0-27 months). The median overall survival time was 16 months (3-28 months). 4 patients suffered from pulmonary infection after treatment and then were all cured after treatment with anti-infective therapy. The 5 patients treated by CAG regimen alone achieved complete remission,3 patients achieved partial remission, 2 patients showed non-reaction. The complete remission rate was 50.0% and overall response rate was 80.0%. The median time of disease free survival was 6 months(0-18 months). The median overall survival time was 13 months(3-31 months), 4 patients suffered from pulmonary infection, 1 patient suffered from enteric infection and 1 patient suffered from Escherichia coli septicemia after treatment, all of them becomed better after active treatment. Two groups of patients all had no serious adverse reactions, All patients could tolerate, no

  13. The mechanism of different priming protocols inducing apoptosis of leukemia cell lines in vitro%不同预激方案诱导白血病细胞株凋亡的机制研究

    Institute of Scientific and Technical Information of China (English)

    蔡佳翌; 陈芳源; 钟济华; 倪蓓文; 钟华; 王海嵘


    Objective: To investigate the effects of different priming protocols on acute myeloid leukemia (AML) cell line HL-60 and acute monocytic leukemia (AMOL) cell line U937 in vitro, and to explore the possible mechanism.Methods: Both of HL-60 and U937 cells were treated with eight protocols, respectively, including with no drugs (as the control), single cytosine arabinoside (Ara-C),single aclarubicin (Acla), single mitoxantrone (Mito), CA regimen (Ara-C+Acla), MA regimen (Mito+Ara-C), CAG regimen [granulocyte-colony stimulating factor (G-CSF) priming combined with Ara-C and Acla]and MAG regimen (G-CSF priming combined with Mito and Ara-C).The morphological changes of HL-60 and U937 cells were observed after different treatment modalities for 24 and 48 h, respectively.The growth inhibition rates of HL-60 and U937 cells were determined by cell count kit-8 assay.The apoptosis rate, the expression rate of cellular surface specific antigen CD1 1b, the apoptosis-associated mitochondrial membrane potential (by JC-1 method) and the activity of caspase-3 were determined by flow cytometry.Results: After treatment with CAG or MAG regimen for 48 h, the morphology of HL-60 and U937 cells showed that the apoptotic bodies were increased.The growth of HL-60 and U937 cells was all inhibited in different drug-using groups, and the cell survival rates in CAG and MAG regimen groups were significantly decreased in a time-dependent manner.Except for the single Ara-C group, the apoptosis rates of U937 cells were higher than those of HL-60 cells in the other different drug-using groups, but the CD1 1 b expression rate was similar.The mitochondrial membrane potentials of HL-60 and U937 cells were decreased by CAG or MAG regimen induction, and this effect was stronger in CAG or MAG regimen group than in the single-drug groups and the control group (P<0.05).The fluorescence intensities of caspase-3 in CAG and MAG regimen groups and the single-drug groups were higher than that in the control

  14. Elderly hematic myeloid tumor patients treated with decitabine and reduced-dose CAG regimen%地西他滨联合减量CAG方案治疗老年血液髓系肿瘤

    Institute of Scientific and Technical Information of China (English)

    黄涛; 刘德斌


    Objective:To study the curative effect and safety of decitabine and reduced-dose CAG regimen for elderly hematic myeloid tumor patients.Methods:10 cases of elderly hematic myeloid tumor patients were treated with decitabine and reduced-dose CAG regimen[decit-abine 15-20mg/(m2· d),qd,iv,d1-5;aclarubicin 10mg/d,qd,iv,d1-4;Ara-C 10mg/m2,q12h,iv,d1-10;G-CSF 300ug/d,qd,ih,d1-10].Results:1 case lasted for 6 courses,and 2 cases lasted for 4 courses,4 cases lasted for 3 courses,and 2 cases lasted for 2 courses,1 case las-ted for 1 course.There were 3 cases of CR(1 case of MDS,2 cases of AML),5 cases of PR(3 cases of MDS,2 cases of AML),2 cases of NR(1 case of AML,1 case of MDS/MPD,died of lung infection).Conclusion:Decitabine and reduced-dose CAG regimen should be an effective treat-ment of the elderly hematic myeloid tumor patients with high safety and tolerable treatment-related mortality.%目的:观察地西他滨联合减量CAG方案治疗老年血液髓系肿瘤的疗效和安全性。方法:10例老年血液髓系肿瘤患者应用地西他滨+减量CAG方案[地西他滨15~20mg/(m2· d),1天1次静注,d1~5;阿克拉霉素10mg/d,1天1次静注,d1~4;阿糖胞苷10mg/m2,12小时1次,静注,d1~10;G-CSF 300ug/d,1天1次,皮下注射,d1~10]。观察患者疗效及不良反应。结果:1例使用6个疗程,2例使用4个疗程,4例使用3个疗程,2例使用2个疗程,1例使用1个疗程,其中3例获完全缓解(1例MDS,2例AML),5例获部分缓解(3例MDS,2例AML),2例疾病进展(1例AML,1例MDS/MPD),最后因肺部感染死亡。结论:地西他滨联合减量CAG方案治疗老年血液髓系肿瘤,疗效良好,不良反应可耐受,值得尽早应用。